Validation of the Chinese Version of Addenbrooke's Cognitive Examination-Revised for Screening Mild Alzheimer's Disease and Mild Cognitive Impairment

2013 ◽  
Vol 37 (3-4) ◽  
pp. 223-231 ◽  
Author(s):  
Rong Fang ◽  
Gang Wang ◽  
Yue Huang ◽  
Jun-Peng Zhuang ◽  
Hui-Dong Tang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Chinese Version ◽  
Addenbrooke’S Cognitive Examination

[P3-441]: THE ADDENBROOKE's COGNITIVE EXAMINATION-REVISED (ACE-R) IN THE DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER's DISEASE: A PRELIMINARY ANALYSIS

2017 ◽  
Vol 13 (7S_Part_23) ◽  
pp. P1138-P1138
Author(s):  
Viviane Amaral Carvalho ◽  
Luciano Inácio Mariano ◽  
Thais Bento Lima-Silva ◽  
Henrique Cerqueira Guimaraes ◽  
Leonardo Cruz de Souza ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Preliminary Analysis ◽  
Addenbrooke’S Cognitive Examination

Addenbrooke's cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests

2016 ◽  
Vol 29 (1) ◽  
pp. 105-113 ◽  
Author(s):  
Jordi A. Matias-Guiu ◽  
Ana Cortés-Martínez ◽  
Maria Valles-Salgado ◽  
Teresa Rognoni ◽  
Marta Fernández-Matarrubia ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Neuropsychological Tests ◽  
Pearson Correlation ◽  
Amnestic Mild Cognitive Impairment ◽  
Visuospatial Function ◽  
Early Stages ◽  
Addenbrooke’S Cognitive Examination

ABSTRACTBackground:Addenbrooke's Cognitive Examination III (ACE-III) is a screening test that was recently validated for diagnosing dementia. Since it assesses attention, language, memory, fluency, and visuospatial function separately, it may also be useful for general neuropsychological assessments. The aim of this study was to analyze the tool's ability to detect early stages of Alzheimer's disease and to examine the correlation between ACE-III scores and scores on standardized neuropsychological tests.Methods:Our study included 200 participants categorized as follows: 25 healthy controls, 48 individuals with subjective memory complaints, 47 patients with amnestic mild cognitive impairment and 47 mild Alzheimer's disease, and 33 patients with other neurodegenerative diseases.Results:The ACE-III memory and language domains were highly correlated with the neuropsychological tests specific to those domains (Pearson correlation coefficient of 0.806 for total delayed recall on the Free and Cued Selective Reminding Test vs. 0.744 on the Boston Naming Test). ACE-III scores discriminated between controls and patients with amnestic mild cognitive impairment (AUC: 0.906), and between controls and patients with mild Alzheimer's disease (AUC: 0.978).Conclusion:Our results suggest that ACE-III is a useful neuropsychological test for assessing the cognitive domains of attention, language, memory, and visuospatial function. It also enables detection of Alzheimer's disease in early stages.

scholarly journals Reliability of Addenbrooke's Cognitive Examination III in differentiating between dementia, mild cognitive impairment and older adults who have not reported cognitive problems

2021 ◽  
Author(s):  
C. Potts ◽  
J. Richardson ◽  
R. B. Bond ◽  
R. K. Price ◽  
M. D. Mulvenna ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Vascular Dementia ◽  
Mixed Dementia ◽  
People With Dementia ◽  
Health And Social Care ◽  
Attention Memory ◽  
Addenbrooke’S Cognitive Examination

AbstractDiagnosing dementia can be challenging for clinicians, given the array of factors that contribute to changes in cognitive function. The Addenbrooke’s Cognitive Examination III (ACE-III) is commonly used in dementia assessments, covering the domains of attention, memory, fluency, visuospatial and language. This study aims to (1) assess the reliability of ACE-III to differentiate between dementia, mild cognitive impairment (MCI) and controls and (2) establish whether the ACE-III is useful for diagnosing dementia subtypes. Client records from the Northern Health and Social Care Trust (NHSCT) Memory Service (n = 2,331, 2013–2019) were used in the analysis including people diagnosed with Alzheimer’s disease (n = 637), vascular dementia (n = 252), mixed dementia (n = 490), MCI (n = 920) and controls (n = 32). There were significant differences in total ACE-III and subdomain scores between people with dementia, MCI and controls (p < 0.05 for all), with little overlap between distribution of total ACE-III scores (< 39%) between groups. The distribution of total ACE-III and subdomain scores across all dementias were similar. There were significant differences in scores for attention, memory and fluency between Alzheimer’s disease and mixed dementia, and for visuospatial and language between Alzheimer’s disease–vascular dementia (p < 0.05 for all). However, despite the significant differences across these subdomains, there was a high degree of overlap between these scores (> 73%) and thus the differences are not clinically relevant. The results suggest that ACE-III is a useful tool for discriminating between dementia, MCI and controls, but it is not reliable for discriminating between dementia subtypes. Nonetheless, the ACE-III is still a reliable tool for clinicians that can assist in making a dementia diagnosis in combination with other factors at assessment.

scholarly journals The Mini-Addenbrooke’s Cognitive Examination (M-ACE) as a brief cognitive screening instrument in Mild Cognitive Impairment and mild Alzheimer’s disease

2018 ◽  
Vol 12 (4) ◽  
pp. 368-373
Author(s):  
Diane da Costa Miranda ◽  
Sonia Maria Dozzi Brucki ◽  
Mônica Sanches Yassuda
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Screening Test ◽  
Area Under The Curve ◽  
Cognitive Screening ◽  
Healthy Elderly ◽  
Administration Time ◽  
Addenbrooke’S Cognitive Examination

ABSTRACT The Mini-Addenbrooke’s Cognitive Examination (M-ACE) is a brief cognitive screening test that evaluates four main cognitive domains (orientation, memory, language and visuospatial function) with a maximum score of 30 points and administration time of five minutes. Objective: To assess the performance of healthy elderly, MCI patients and mild AD patients using the Brazilian version of the M-ACE. Methods: The test was applied to a group of 36 Mild Cognitive Impairment (MCI), 23 mild Alzheimer’s Disease (AD) and 25 cognitive healthy elderly. All participants were aged ≥60 years. Results: The M-ACE displayed high internal consistency (Cronbach alpha >0.8; 95% CI 0.7-0.8) and proved effective for differentiating the AD group from MCI and control groups, providing superior accuracy than the MMSE (the cut-off point of 20 points had the highest sensitivity and specificity – 95.6% and 90.16% respectively, with a high area under the curve – AUC=0.8; 95% CI 0.7-0.9). Performance on the M-ACE was strongly correlated with that of the MMSE and Functional Activities Questionnaire (FAQ). The M-ACE was not accurate in discriminating MCI from control subjects. Conclusion: The M-ACE is a brief screening test which provided high accuracy for diagnosing AD in this sample. The suggested cut-off point in this study was 20 points for AD.

Reliability and Validity of the Chinese Version of Mild Behavioral Impairment Checklist in Mild Cognitive Impairment and Mild Alzheimer’s Disease

2021 ◽  
pp. 1-9
Author(s):  
Lujie Xu ◽  
Tao Li ◽  
Lingchuan Xiong ◽  
Xiao Wang ◽  
Zahinoor Ismail ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Chinese Culture ◽  
Structural Reliability ◽  
Reliability And Validity ◽  
Chinese Version ◽  
Behavioral Impairment ◽  
Good Reliability

Background: Mild behavioral impairment (MBI) has been proposed as an early manifestation of dementia. The Mild Behavioral Impairment Checklist (MBI-C) may help identify MBI in prodromal and preclinical dementia. Objective: The study aimed to evaluate the reliability and validity of the Chinese version of MBI-C in mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD), and to explore the structure of the five factors of the MBI-C in Chinese culture. Methods: Sixty dyads of MCI and mild AD (MCI, n = 33; mild AD, n = 35) were recruited. The informants completed the MBI-C and Neuropsychiatric Inventory Questionnaire (NPI-Q) and were interviewed for clinician rating of the NPI. The Cronbach’s coefficient was used to measure the structural reliability of the MBI-C. The criterion-validity was evaluated with the correlation coefficient between the MBI-C and the total scores of NPI-Q and NPI. Exploratory factor analysis was conducted to investigate the structure of the MBI-C. Results: The Cronbach’s α coefficient was 0.895. The MBI-C total score was positively correlated with all five domains (r = 0.577∼0.840). The total score of MBI-C was significantly correlated with the total scores of NPI-Q (r = 0.714) and NPI (r = 0.749). Similarly, the five domain scores of MBI-C were significantly correlated with the factor and total scores of NPI-Q (r = 0.312∼0.673) and NPI (r = 0.389∼0.673). The components of each factor in Chinese version of MBI-C were slightly different from those of the a priori defined domains (χ2 = 1818.202, df = 496, p < 0.001). Conclusion: The Chinese version of MBI-C has good reliability and validity, and can be used to evaluate the psychological and behavioral changes in MCI and mild AD.

Sign in / Sign up

Export Citation Format

Share Document